AABB 2005: new products, techniques and automation on the agenda
This article was originally published in Clinica
Executive Summary
Tools for safer blood products, emerging technologies and automation were among the key themes at the annual AABB exhibition and meeting on October 14-18 2005, in Seattle, Washington, which attracted 3% more attendees (7,049), 17% of them hailing from outside the US. HBV NAT and bacterial contamination testing were major topics of discussion from a clinical issues standpoint, and there was much new product approval and launch news during what was an exciting show, writes Kerri Weinert and Carrie Cresenzi, of Boston Biomedical Consultants Inc
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.